Navigation Links
Japanese Fund Moves Quickly to Invest in Promising Technology Against Malaria, Tuberculosis And Chagas Disease
Date:11/7/2013

immune response to the original BK-SE36. The research team will use the new grant to test whether adding CpG, a substance known as an adjuvant, can boost the subjects' response to the vaccine. Researchers agree that a vaccine is desperately needed to check malaria's spread in the developing world, as part of a multipronged approach that includes other tools like bednets, sprays and antimalarial drugs.

The second investment will go to Japan's Ehime University and the biotech company CellFree Sciences, both located in Matsuyama, Ehime Prefecture, in partnership with PATH, based in Seattle, Washington, for work with its Malaria Vaccine Initiative. The Fund will invest US$600,000 to identify novel targets of immunity and accelerate the development of malaria vaccines to support elimination and eradication. The project addresses one of the main challenges in developing malaria vaccines, in that only a tiny percentage of potential targets on the parasite surface have been screened for their vaccine potential. Scientists at Ehime University have developed an innovative wheat germ cell-free protein synthesis technology, which has proven to be highly effective in producing large numbers of high quality Plasmodium proteins. Using this technology, the partnership will produce specific proteins for the purpose of developing monoclonal antibodies that will be evaluated for their ability to block parasites from invading liver cells. This would enable prioritization of antigens for future vaccine development.

The third and largest award, of approximately US$2.6 million, was granted to Medicines for Malaria Venture (MMV) in partnership with Takeda Pharmaceutical Company Limited (Takeda) to study a promising new anti-malarial compound, DSM265, to clinical proof-of-concept stage. New compounds are urgently needed to fight malaria, as resistance to current medicines is growing. Artemisinin combination therapies
'/>"/>

SOURCE Global Health Innovative Technology Fund (GHIT Fund)
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Japanese Market for Orthopedic Soft Tissue Repair & Sports Medicine
2. The Japanese Cancer Association and Debiopharm Group Present Doctors Oshima and Tanaka with the 2012 JCA-Mauvernay Award for their Innovative and Outstanding Cancer Research
3. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
4. Neuland Labs Strengthens Commitment to Japanese Market With New Manufacturing Collaboration With Mitsubishi Healthcare Unit API Corporation
5. Reimbursement Cuts Will Challenge Japanese Interventional Cardiology Device Market
6. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
7. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
8. Japanese Heart Valve Device Market Growth Will Spike With The Launch of Transcatheter Heart Valves
9. The Japanese Market For Peripheral Vascular Devices Will Be Characterized By New Product Launches In Many Segments
10. The Japanese Embolization Particle Market Will Witness Significant Market Activity And Rapid Growth Due To New Product Approvals
11. SMT C1100 For Duchenne Muscular Dystrophy Moves To Human Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 25, 2014 ... Instruments Market by Power Source (Electric, Battery, Pneumatic), ... Cables, Blade, Burr, Cart), by Application (Orthopedic, ENT, ... published by MarketsandMarkets, the global Powered Surgical Instruments Market ... $1.6 Billion in 2014 and is expected to ...
(Date:11/26/2014)... Calif. , Nov. 25, 2014 /PRNewswire/ ... company focused on the development of mobile ... accurate testing in hospital and pre-hospital settings, ... Organization (ISO) 13485:2003 certification.  The certification was ... one of the world,s leading certification bodies. ...
(Date:11/26/2014)... OAKS, Calif. and LONDON , ... ) and AstraZeneca (NYSE: AZN ) today announced ... evaluating two doses of brodalumab in more than 1,800 patients ... with both Stelara ® (ustekinumab) and placebo at week ... brodalumab weight-based analysis group were each shown to be superior ...
Breaking Medicine Technology:Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... 5 ARKRAY, Inc., the world,s 5th largest manufacturer of ... clearance from the US Food and Drug Administration for its ... meter and strip platform, which ARKRAY will make available for ... complement to the existing GLUCOCARD line of products, and will ...
... 5 Cardiac Science Corporation (Nasdaq: ... ( AED ) and diagnostic cardiac monitoring devices, ... Jr., to its board of directors. Andrews replaces long-time board ... seat effective November 5th. The total number of directors remains ...
Cached Medicine Technology:ARKRAY, Inc. Receives FDA Clearance for New GLUCOCARD(R) Vital(TM) Blood Glucose Monitoring System 2Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 2Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 3Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 4Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 5
(Date:11/26/2014)... (PRWEB) November 26, 2014 The ... Cardiology have launched a partnership designed to improve ... for congestive heart failure (CHF) patients in the ... staff and Lourdes Cardiology team will help CHF ... supervised protocols. This partnership pairs the Cardiac Recovery ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Increasing ... stringent drug safety regulations are expected to be ... period. Growing prevalence of acute and chronic ailments ... for new drug development. Moreover, growing adverse drug ... the same has become the need of the ...
(Date:11/26/2014)... Raleigh, NC (PRWEB) November 26, 2014 ... types of materials science can cause mesothelioma that looks ... just posted a new article on the research. ... at the Fraunhofer Institute for Toxicology and Experimental Medicine ... nanotubes. While all of the rats eventually ...
(Date:11/26/2014)... The city of San Diego, California, because ... with a plan to recycle wastewater – also called ... supports the San Diego plan as part of her ... Kleyne, by recycling water that San Diego already owns, ... greatly reduced. (Spagat, E, “San Diego looks to sewers ...
(Date:11/26/2014)... 26, 2014 Loffler Companies has been ... in Imaging, an online information and news publication for ... the sixth consecutive year Loffler has earned this prestigious ... The Elite Dealer Awards honor the best and the ... Elite Dealer honorees were chosen for their innovative marketing ...
Breaking Medicine News(10 mins):Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 2Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 3Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 3Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2
... By Amanda Gardner HealthDay Reporter , ... announced Thursday that they will lower the maximum amount ... products such as Vicodin and Percocet because of reports ... three years, the upper threshold of acetaminophen in prescription ...
... high blood pressure, according to new research by the University ... pressure or hypertension is one of the major ... and costs more than $300 billion each year. Around a ... 10 million people in the UK and one in three ...
... News) -- The more you walk, the lower your risk ... middle-aged adults who participated in a study to map diabetes ... health examination at the start of the study and provided ... were also given a pedometer and instructed how to use ...
... Randy Dotinga HealthDay Reporter , THURSDAY, Jan. ... severely obese women who suffer from incontinence, a new ... after undergoing gastric-band weight-loss surgery. "This could ... said Dr. Weranja K.B. Ranasinghe, the study,s lead author. ...
... Massachusetts General Hospital (MGH) Cancer Center researchers have discovered a ... of certain DNA sequences that do not code for proteins. ... been studied for their role in chromosomal structure but previously ... The report will appear in the journal Science ...
... News) -- Differences in income, gender and race influence ... a federal government report released Thursday shows. While ... healthy lives, disparities persist, according to the U.S. Centers ... people have five to 11 times fewer healthy days ...
Cached Medicine News:Health News:FDA Lowers Amount of Acetaminophen Allowed in Prescription Painkillers 2Health News:FDA Lowers Amount of Acetaminophen Allowed in Prescription Painkillers 3Health News:Bioactive compounds in berries can reduce high blood pressure 2Health News:The More You Walk, the Lower Your Diabetes Risk: Study 2Health News:Weight-Loss Surgery May Ease Incontinence in Women 2Health News:Weight-Loss Surgery May Ease Incontinence in Women 3Health News:Overexpression of repetitive DNA sequences discovered in common tumor cells 2Health News:Health Disparities Persist in U.S., Report Shows 2
Midstream Catch Kits...
... The BladderScan BVM ... and noninvasively to determine ... weight) and bladder volume ... The BVM 6500 was ...
... Silver Wire Coil and helix ... prevents buckling.,Unique Silver Wire Construction eliminates ... Shaped Tip is designed to provide ... natural, aesthetic result. ,Trimmable ...
... uniquely designed two-piece inflatable prosthesis consisting of ... corpora cavernosa and a single pump bulb ... the pump to inflate and bend the ... fluid-filled system allows for good rigidity and ...
Medicine Products: